KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $511.9 million.

  • Biogen's Cash from Operations fell 3272.44% to $511.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year decrease of 2333.16%. This contributed to the annual value of $2.2 billion for FY2025, which is 2333.16% down from last year.
  • Per Biogen's latest filing, its Cash from Operations stood at $511.9 million for Q4 2025, which was down 3272.44% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Biogen's Cash from Operations registered a high of $1.3 billion during Q3 2025, and its lowest value of -$175.0 million during Q4 2022.
  • For the 5-year period, Biogen's Cash from Operations averaged around $582.6 million, with its median value being $609.1 million (2023).
  • As far as peak fluctuations go, Biogen's Cash from Operations crashed by 12087.56% in 2022, and later surged by 598720.0% in 2024.
  • Biogen's Cash from Operations (Quarter) stood at $838.3 million in 2021, then crashed by 120.88% to -$175.0 million in 2022, then surged by 107.14% to $12.5 million in 2023, then skyrocketed by 5987.2% to $760.9 million in 2024, then crashed by 32.72% to $511.9 million in 2025.
  • Its last three reported values are $511.9 million in Q4 2025, $1.3 billion for Q3 2025, and $160.9 million during Q2 2025.